Control of the immune response by pro-angiogenic factors.
The progressive conversion of normal cells into cancer cells is characterized by the acquisition of eight hallmarks. Among these criteria, the capability of the cancer cell to avoid the immune destruction has been noted. Thus, tumors develop mechanisms to become invisible to the immune system, such as the induction of immunosuppressive cells, which are able to inhibit the development of an efficient immune response. Molecules produced in the tumor microenvironment are involved in the occurrence of an immunosuppressive microenvironment. Recently, it has been shown that vascular endothelial growth factor A (VEGF-A) exhibits immunosuppressive properties in addition to its pro-angiogenic activities. VEGF-A can induce the accumulation of immature dendritic cells, myeloid-derived suppressor cells, regulatory T cells, and inhibit the migration of T lymphocytes to the tumor. Other pro-angiogenic factors such as placental growth factor (PlGF) could also participate in tumor-induced immunosuppression, but only few works have been performed on this point. Here, we review the impact of pro-angiogenic factors (especially VEGF-A) on immune cells. Anti-angiogenic molecules, which target VEGF-A/VEGFR axis, have been developed in the last decades and are commonly used to treat cancer patients. These drugs have anti-angiogenic properties but can also counteract the tumor-induced immunosuppression. Based on these immunomodulatory properties, anti-angiogenic molecules could be efficiently associated with immunotherapeutic strategies in preclinical models. These combinations are currently under investigation in cancer patients.
INSERM U970, PARCC (Paris Cardiovascular Research Center), Université Paris-Descartes, Sorbonne Paris Cité , Paris , France.
Thibault
T
Voron
INSERM U970, PARCC (Paris Cardiovascular Research Center), Université Paris-Descartes, Sorbonne Paris Cité , Paris , France.
Elie
E
Marcheteau
INSERM U970, PARCC (Paris Cardiovascular Research Center), Université Paris-Descartes, Sorbonne Paris Cité , Paris , France ; Service d'Hépatogastroentérologie et d'Oncologie Digestive, Hôpital Européen Georges Pompidou , Paris , France.
Simon
S
Pernot
INSERM U970, PARCC (Paris Cardiovascular Research Center), Université Paris-Descartes, Sorbonne Paris Cité , Paris , France ; Service d'Hépatogastroentérologie et d'Oncologie Digestive, Hôpital Européen Georges Pompidou , Paris , France.
Orianne
O
Colussi
INSERM U970, PARCC (Paris Cardiovascular Research Center), Université Paris-Descartes, Sorbonne Paris Cité , Paris , France ; Service d'Immunologie Biologique, Hôpital Européen Georges Pompidou , Paris , France.
Eric
E
Tartour
INSERM U970, PARCC (Paris Cardiovascular Research Center), Université Paris-Descartes, Sorbonne Paris Cité , Paris , France ; Service d'Hépatogastroentérologie et d'Oncologie Digestive, Hôpital Européen Georges Pompidou , Paris , France.
Julien
J
Taieb
INSERM U970, PARCC (Paris Cardiovascular Research Center), Université Paris-Descartes, Sorbonne Paris Cité , Paris , France.
Magali
M
Terme
MDSC; PlGF; VEGF-A; immunosuppression; immunotherapy; pro-angiogenic factors; regulatory T cells; tumor